Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Long-Term Extension of ABBV-105 Alone or with Upadacitinib in Rheumatoid Arthritis
2018-002306-31Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ABBV-105 monotherapy with ABBV-105 + Upadacitinib combination (2 arms). Primary endpoint: Change in DAS28-CRP from baseline of Study M16-063. Started Feb 2019; status: completed.
02
Drugs
elsubrutinibupadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-002306-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002306-31.